This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ArGEN-X Grants Licenses To Its NHance™ Antibody Half-Life Extension Technology

BREDA, The Netherlands, August 6, 2013 /PRNewswire/ --

Meeting The Increasing Demand For Technologies That Enable Antibody Product Differentiation

arGEN-X, a clinical stage biopharmaceutical company specialized in the creation and development of highly differentiated human antibody therapeutics, today announces the signing of its second non-exclusive license agreement for its antibody half-life extension technology, NHance™. Both licenses granted to date are with companies dedicated to developing and commercializing antibody-based therapeutics with clear clinical benefits.

Under the terms of these agreements, arGEN-X receives upfront technology access and annual license maintenance fees, in addition to clinical milestone payments and tiered royalties on product sales. No further details are being disclosed.

Commenting on today's announcement, Tim Van Hauwermeiren, CEO of arGEN-X, said:

"Since our recent launch of NHance™, we have witnessed considerable interest from companies seeking to develop antibody therapeutics with best in class attributes. As a novel, validated approach to optimizing antibody pharmacokinetics, NHance™ delivers longer drug residence times in the body, enabling less frequent subcutaneous dosing, improved patient convenience and attractive pharmacoeconomics. In addition to applying NHance™ to our own pipeline programs, we intend to exploit our unique IP position by commercializing the technology both through arms length licensing and broader antibody discovery collaborations. We are therefore pleased to enter into these agreements and fully expect to generate further NHance™ partnerships in the future."

About NHance™

NHance™is an arGEN-X proprietary technology capable of increasing the half life of a therapeutic antibody in the human systemic circulation. NHance™ achieves this through 2 specific mutations in the antibody Fc region (at His433 and Asn434), resulting in an improved affinity of antibody binding to the neonatal Fc receptor at acidic pH. This receptor is responsible for recycling the antibody within the human body. Enhanced antibody serum levels resulting from prolonged half-life may lead to a higher therapeutic effect, lower material requirements for the same therapeutic effect, and/or reduced dosing frequency. The technology may also further enhance antibody transport across mucosal barriers, enabling alternative routes of antibody product administration.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs